In a randomized controlled trial of patients with dyslipidemia assigned to either extended release niacin ( ERN ) alone , ERN combined with the selective prostaglandin D@ receptor subtype @ inhibitor laropiprant ( ERN-L ) or placebo , niacin lowered serum phosphorus ; however , it is not known if it lowers FGF@ concentrations .